GlassScriptPhysician profile
Craig Woo
NPI 1063131852
$7,675.14
in general payments reported to CMS, 2019-2025
31 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $49.25 · 2023: $1,469 · 2024: $2,986 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,625.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,023.97 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $842.71 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $718.52 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $651.44 | 2023-2025 | Cuvitru, Hyqvia, Takhzyro |
| Abbvie INC. | $590.50 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.94 | 2023-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $389.00 | 2023-2025 | Orladeyo |
| Grifols USA, LLC | $261.74 | 2024-2025 | Xembify |
| Blueprint Medicines Corporation | $250.88 | 2023-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $248.98 | 2025 | Neffy |
| Amgen INC. | $245.12 | 2023-2025 | Tezspire |
| Csl Behring | $242.48 | 2023-2025 | Hizentra, Haegarda |
| Pfizer INC. | $221.17 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $219.45 | 2025 | |
| Incyte Corporation | $199.00 | 2023-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $198.71 | 2023-2025 | Xolair |
| Hikma Pharmaceuticals USA | $163.37 | 2023-2025 | Ryaltris |
| Galderma Laboratories, L.P. | $158.31 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $97.54 | 2024-2025 | Ruconest |
| Lilly USA, LLC | $90.24 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $82.14 | 2023-2025 | Adbry |
| Kaleo, INC. | $72.02 | 2024 | Auvi-Q |
| Kedrion Biopharma, INC. | $60.51 | 2025 | Gammaked, Kedrab, Koate |
| Sanofi Pasteur INC. | $49.25 | 2022 | |
| Octapharma USA, INC. | $38.70 | 2023-2024 | Cutaquig, Panzyga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2024 | Spiriva Respimat |
| X4 Pharmaceuticals, INC. | $30.44 | 2024 | Xolremdi |
| Jubilant Hollisterstier LLC | $30.35 | 2024 | |
| Insmed, INC. | $22.47 | 2025 | Brinsupri, Arikayce |
| Phadia US INC. | $18.26 | 2024 | Immunocap |
| Optinose US, INC. | $15.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.